1. Introduction

Biotech contract dispute resolution clauses are contractual provisions that establish how disputes between biotechnology companies, pharmaceutical manufacturers, research institutions, universities, investors, laboratories, clinical-trial sponsors, and technology licensors must be resolved.

Biotechnology contracts frequently involve complex technical and commercial relationships, including:

Research and development (R&D) agreements.

Patent, gene-editing, and biotechnology licensing agreements.

Clinical-trial and contract research organization (CRO) agreements.

Biosimilar manufacturing and supply contracts.

Biological sample and biobank agreements.

Confidentiality, trade-secret, and data-sharing agreements.

Joint ventures, technology transfers, and milestone-based investments.

Regulatory compliance, product recalls, and quality-control obligations.

Disputes in these contracts can concern scientific performance, ownership of inventions, failed experiments, research milestones, royalty calculations, intellectual property infringement, defective biological products, confidentiality breaches, or delayed regulatory approvals.

A carefully drafted dispute resolution clause determines which disputes can be referred to arbitration, which court can grant urgent relief, what technical evidence is required, and how an enforceable final decision can be obtained.

The principal focus of this explanation is Indian law, supplemented by relevant foreign decisions and international biotechnology dispute-resolution practice.

2. Legal framework governing biotech dispute resolution in India

The following statutes are particularly important.

The governing law depends on the contractual relationship, the subject matter of the dispute, the chosen dispute-resolution mechanism, and any mandatory statutory rules.

Under Sections 7 and 16 of the Arbitration and Conciliation Act, 1996, an arbitration agreement must be in writing, and the arbitration clause is generally treated as legally separable from the principal contract. Section 16 also recognizes the arbitral tribunal's power to rule on its own jurisdiction.

VoxJuris+1

An important distinction follows: a dispute arising from a biotech contract is not automatically arbitrable merely because the contract contains an arbitration clause. The nature of the requested remedy and any exclusive statutory jurisdiction must also be considered.

3. Major types of biotech contract disputes

2026 Biological Sciences Degree Master's Programs Accepting Students Now | Research.com

A. Research and development disputes

These involve failure to meet research milestones, disagreements over experimental protocols, reproducibility, delayed delivery of results, or disputes over whether a project has achieved its contracted scientific objectives.

Example: A biotechnology company refuses to pay a milestone fee because the contractor's enzyme-development project failed to meet the agreed activity threshold.

What Does a Contract Mean in Biotech—and Why One Missing Clause Could Cost You Everything in China

B. Intellectual property and licensing disputes

These concern patent ownership, licence scope, royalty payments, background and foreground IP, improvements, sublicensing, infringement, and post-termination use of technology.

Example: A licensee develops an improved biological manufacturing process and disputes whether the improvement belongs to the licensor.

Pharma Manufacturing Quality Compliance

C. Manufacturing and supply disputes

These concern product purity, contamination, potency, batch failures, cold-chain interruptions, delayed deliveries, recall expenses, and compliance with quality standards.

Example: A manufacturer claims that a failed vaccine batch resulted from the buyer's improper storage rather than a manufacturing defect.

日本TCS、AIを活用した医薬品開発・安全性業務向けソリューションの提供を開始 - プレスリリース | 日本タタ・コンサルタンシー・サービシズ

D. Clinical-trial and research-services disputes

These may involve recruitment targets, protocol deviations, informed-consent obligations, data integrity, adverse-event reporting, confidentiality, or delayed trial completion.

Example: A sponsor alleges that a CRO failed to preserve the integrity of clinical-trial records.

Other disputes may concern regulatory warranties, indemnification, biological sample access, data ownership, publication rights, technology-transfer obligations, and termination following a change in regulatory requirements.

4. Essential components of an effective dispute resolution clause

A biotech contract should not simply state that “all disputes shall be settled amicably.” It should specify a complete and workable procedure.

4.1 Scope of disputes

The clause should identify which contractual disputes are covered.

A broad clause may include disputes concerning:

Interpretation, performance, and breach of contract.

Research milestones and acceptance criteria.

Royalty payments and accounting.

Ownership and permitted use of intellectual property.

Confidentiality and trade secrets.

Manufacturing defects, batch rejection, and product quality.

Termination, indemnification, and damages.

The wording should also cover disputes concerning the agreement's validity, termination, and enforceability, to the extent legally permissible.

Drafting principle: A broad arbitration clause can cover many contractual claims, but it cannot automatically confer jurisdiction over third parties or override mandatory statutory remedies.

4.2 Negotiation and escalation

Before arbitration, parties may require negotiations between designated senior executives.

For example, the parties may agree to:

Issue a written dispute notice.

Refer the dispute to project managers for initial resolution.

Escalate unresolved disputes to senior executives within 15 days.

Proceed to mediation or arbitration if the dispute remains unresolved after a specified period.

The contract should state whether these steps are mandatory conditions precedent or merely encouraged procedures. It should also specify when the escalation period expires and what happens if one party refuses to participate.

In Perkin Elmer US LLC v. Ilishan Biotech Private Limited, an Indian High Court considered objections that arbitration had been invoked without satisfying a negotiation provision. The court examined the actual language of the clause and the correspondence between the parties, distinguishing a genuine condition precedent from wording that merely expressed an intention to negotiate.

Indian Kanoon

This is particularly relevant to biotech contracts where disagreements may arise gradually during a lengthy research or licensing relationship.

4.3 Mediation

Mediation uses a neutral mediator to help the parties negotiate a settlement. The mediator does not ordinarily impose a binding decision.

Mediation can be useful when the parties want to preserve a valuable scientific collaboration, continue manufacturing, protect confidential research, or agree on revised milestones.

A well-drafted clause should address:

Appointment of the mediator.

The institution or mediation rules to be used.

The period allowed for mediation.

Confidentiality and permitted disclosure of mediation communications.

The effect of a settlement agreement.

The right to seek urgent interim relief without waiting for mediation.

The Mediation Act, 2023, is relevant to India's mediation framework, subject to its applicable commencement provisions and rules. Cross-border contracts should separately consider the legal enforceability of any international mediated settlement.

4.4 Arbitration

Arbitration is a private adjudicatory process in which an impartial tribunal determines the dispute and issues an award that can generally be enforced under the applicable arbitration law.

A biotech arbitration clause should identify:

The seat of arbitration.

The applicable procedural rules or administering institution.

The number of arbitrators.

The appointment procedure.

The language of proceedings.

The governing substantive law.

The treatment of confidential scientific evidence.

Interim relief and emergency procedures, where available.

Allocation of costs and legal fees.

Under Section 7 of the Arbitration and Conciliation Act, 1996, the arbitration agreement must be in writing. Written electronic communications can satisfy that requirement when the statutory conditions are met.

IndiaCode+1

4.5 Expert determination

Expert determination is especially valuable when a dispute concerns a technical question rather than a broad legal controversy.

Possible questions include:

Whether a biological product meets an agreed potency specification.

Whether a manufacturing batch satisfies contractual acceptance criteria.

Whether a research milestone has been achieved.

Whether a royalty calculation follows an agreed formula.

Whether a laboratory's testing procedure complies with a specified technical protocol.

The clause should specify the expert's qualifications, appointment procedure, access to laboratory records, testing methodology, conflict-of-interest safeguards, and whether the determination is binding.

Important distinction: Expert determination is not necessarily arbitration. If the parties intend the process to produce an arbitral award, they should draft an arbitration agreement and follow the applicable legal requirements.

4.6 Court jurisdiction and interim relief

Even when arbitration is the agreed final mechanism, courts may be needed for urgent protective measures, supervisory functions, or enforcement.

Under Section 9 of the Arbitration and Conciliation Act, a competent court can grant interim measures in qualifying cases. Section 17 provides for interim measures by the arbitral tribunal.

India Code+1

In a biotech dispute, interim relief might be sought to preserve:

Biological samples or experimental records.

Confidential manufacturing protocols.

Research databases and electronic audit trails.

Evidence of contamination or defective production.

Assets needed to satisfy a potential award.

Contractually protected intellectual property.

A clause should not suggest that an arbitral tribunal can exercise every power available to a regulator or court.

5. Important case laws and their application to biotech contracts

The following decisions establish general principles that can be applied to biotechnology contracts. Unless expressly identified as a biotech-specific dispute, they should not be represented as cases deciding the scientific merits of a biotechnology controversy.

Case 1: Vidya Drolia v. Durga Trading Corporation (2020)

Supreme Court of India · Civil Appeal No. 2402 of 2019 · Decided 14 December 2020

The Supreme Court explained the limited judicial review generally exercised at the referral stage under Sections 8 and 11 of the Arbitration and Conciliation Act. Courts should ordinarily refer parties to arbitration where a valid agreement exists and should avoid conducting a full trial on jurisdiction at that preliminary stage. Clearly non-arbitrable disputes remain an exception.

VoxJuris+1

Application to biotechnology: Suppose a biotech licensor alleges that a licensee failed to pay royalties under a technology licence. If the contract contains a valid arbitration clause, the court will generally respect that dispute-resolution arrangement, subject to the applicable legal exceptions.

However, a dispute over a private contractual payment is different from a request for a public-law determination that affects rights against the world.

Legal principle: Respect party autonomy while preserving statutory limits on arbitrability.

Case 2: Perkins Eastman Architects DPC v. HSCC (India) Ltd. (2019)

Supreme Court of India · Arbitration Petition No. 32 of 2019 · Decided 26 November 2019

The Supreme Court addressed the appointment of arbitrators where an interested party had the unilateral power to appoint the sole arbitrator. It held that a person who is interested in the outcome of the dispute cannot have exclusive authority to appoint a sole arbitrator in circumstances that compromise the required independence and impartiality.

VoxJuris

Application to biotechnology: A pharmaceutical company should not assume that it can appoint the sole arbitrator in a dispute with a smaller contract research organization merely because it drafted the agreement.

A suitable clause should provide for neutral appointment arrangements and compliance with the independence and disclosure requirements of Indian arbitration law.

Legal principle: Arbitrator neutrality and procedural fairness are central to a defensible dispute resolution process.

Case 3: Indus Biotech Private Limited v. Kotak India Venture (Offshore) Fund (2021)

Supreme Court of India · Civil Appeal No. 3076 of 2020 · Decided 26 March 2021

This case involved an investment agreement containing an arbitration clause and a dispute concerning the relationship between arbitration proceedings and insolvency proceedings under the Insolvency and Bankruptcy Code, 2016. The Supreme Court examined whether the insolvency application had reached the stage at which a collective insolvency proceeding had been triggered.

CaseMine

Application to biotechnology: A biotech startup may have shareholders, venture-capital investors, convertible instruments, milestone-based funding, and technology-transfer obligations. Its contracts should distinguish ordinary contractual disputes from matters governed by insolvency legislation or other mandatory statutory procedures.

Legal principle: An arbitration clause does not displace a statutory insolvency process whenever that process has validly commenced.

Case 4: Trimex International FZE Ltd. v. Vedanta Aluminium Ltd. (2010)

Supreme Court of India · Decided 22 January 2010

The Court recognized that a binding commercial contract, including its arbitration agreement, can arise through exchanges of correspondence and electronic communications even where a formal signed contract has not subsequently been executed, provided the parties' communications establish agreement on the essential terms.

IndiaCode+1

Application to biotechnology: Negotiations over licensing, research services, or supply arrangements often occur through emails, purchase orders, technical annexures, and electronic acceptance.

Companies should ensure that their communications clearly state whether a proposal is binding, which terms are accepted, and whether an attached arbitration clause is incorporated into the agreement.

Legal principle: The absence of a later formal signature does not invariably prevent a contract or arbitration agreement from being established.

Case 5: Alchemist Hospitals Ltd. v. ICT Health Technology Services India Pvt. Ltd. (2025)

Supreme Court of India · 2025 INSC 1289

The dispute concerned the wording of a dispute-resolution clause requiring good-faith negotiations and a further arbitration-like procedure involving senior management. The clause also contained a provision concerning recourse to courts after a specified period. The litigation illustrates the importance of determining whether the agreed mechanism constitutes genuine arbitration and how its different stages interact.

VoxJuris

Application to biotechnology: A clause that says a dispute will be decided by the parties' respective chairpersons, followed by court proceedings, may create uncertainty about whether the parties intended a binding arbitral award or merely an internal escalation process.

The contract should expressly state whether the decision-maker acts as an arbitrator, whether the result is binding, and what legal remedies remain available afterward.

Legal principle: A dispute-resolution clause must establish a coherent mechanism rather than combine incompatible procedures without explanation.

Case 6: Booz Allen & Hamilton Inc. v. SBI Home Finance Ltd. (2011)

Supreme Court of India · (2011) 5 SCC 532

The Supreme Court distinguished disputes involving rights in personam, which are generally capable of arbitration, from certain disputes involving rights in rem, which generally require adjudication by courts or statutory tribunals.

Application to biotechnology: A contractual disagreement over royalty payments under a patent licence may be arbitrable. However, a request to invalidate a patent with consequences extending beyond the contracting parties raises different questions. The exact claim, statutory framework, and remedy sought matter.

Legal principle: The presence of an arbitration clause does not make every intellectual property dispute arbitrable.

Case 7: Amgen Inc. v. Apotex Inc. (2016)

United States Court of Appeals for the Federal Circuit · No. 16-1308 · Decided 5 July 2016

This dispute concerned a biosimilar application and the notice period required before commercial marketing under the United States Biologics Price Competition and Innovation Act. The court affirmed an injunction enforcing the statutory 180-day notice requirement after the applicant obtained its biological-product licence.

Justia Law

Application to biotechnology: A contract between a biological-product innovator and a biosimilar developer cannot simply eliminate mandatory statutory requirements through private agreement. A contract may allocate responsibility for regulatory compliance, but it does not replace the applicable legislation.

Legal principle: Regulatory obligations and contractual dispute resolution must be analyzed separately; an arbitral award cannot automatically override mandatory statutory requirements.

International biotechnology dispute-resolution practice

The World Intellectual Property Organization (WIPO) has documented life-sciences mediation and arbitration involving pharmaceutical licensing, research and development, royalty disputes, technology use, supply contracts, confidentiality, and intellectual property issues.

WIPO

This practice illustrates why a biotech dispute-resolution clause may need both legal and scientific expertise.

Useful reference: WIPO Arbitration and Mediation Center — Life Sciences Dispute Resolution.

6. Patent validity, trade secrets, and regulatory disputes: important limits

Biotechnology contracts require particular care because a single commercial dispute can involve contractual rights, intellectual property rights, public regulation, and third-party interests.

The critical distinction is between a tribunal deciding contractual rights between parties and an authority making a determination that the law reserves to a court or regulator.

For instance, an arbitrator might determine whether a licensee owes royalties for using specified gene-editing technology. That does not necessarily mean the arbitrator can grant every form of patent invalidity relief or bind a regulator that was not a party to the arbitration.

7. Model dispute resolution clause for a biotechnology contract

The following is a starting-point drafting example for an Indian commercial biotech agreement. It should be tailored to the contract, the applicable statutory framework, and the parties' bargaining position.

Dispute Resolution

1. Good-faith negotiations. Any dispute, controversy or claim arising out of or in connection with this Agreement, including its interpretation, performance, breach, validity, termination, intellectual property licensing obligations, research milestones, royalty payments, confidentiality obligations or indemnification obligations (a “Dispute”), shall first be notified in writing by the affected Party to the other Party. Authorized senior executives of the Parties shall attempt in good faith to resolve the Dispute within thirty (30) days after receipt of the notice.

2. Mediation. If the Dispute remains unresolved, either Party may refer it to mediation administered by a mutually agreed mediation institution under its applicable rules. Unless the Parties agree otherwise, mediation shall be completed within thirty (30) days of the mediator's appointment. Either Party may proceed to arbitration if the Dispute remains unresolved upon expiry of that period. The mediation requirement shall not prevent a Party from seeking urgent interim relief.

3. Arbitration. Any Dispute not resolved through the foregoing process shall be finally resolved by arbitration under the Arbitration and Conciliation Act, 1996, as applicable. The tribunal shall consist of one independent arbitrator appointed by mutual agreement within thirty (30) days after a written request for arbitration. If the Parties fail to agree on an arbitrator, appointment shall be sought through the procedure prescribed by applicable law. No Party shall have unilateral authority to appoint the sole arbitrator.

4. Seat, venue and language. The juridical seat of arbitration shall be [City, India]. Hearings may be conducted in person or electronically, as directed by the tribunal. The language of the arbitration shall be English.

5. Governing law. This Agreement and the substantive contractual rights and obligations of the Parties shall be governed by the laws of India, subject to applicable mandatory law.

6. Technical evidence and confidentiality. The tribunal may appoint an independent scientific or technical expert where permitted by applicable law and after giving the Parties a reasonable opportunity to be heard. The Parties shall preserve relevant laboratory records, sample identifiers, testing data, electronic audit trails and other material evidence. Confidential information, biological materials and personal data shall be handled in accordance with applicable law and appropriate protective directions.

7. Interim relief. Nothing in this clause prevents either Party from applying to a competent court or the arbitral tribunal for interim or protective relief available under applicable law, including measures to preserve evidence, protect confidential information, or prevent irreparable contractual harm.

8. Regulatory and statutory matters. Nothing in this clause authorizes the tribunal to exercise a power reserved exclusively to a court or statutory authority, bind a non-party without a lawful basis, or require either Party to violate mandatory regulatory obligations.

9. Award and costs. The arbitral tribunal shall issue a reasoned award, subject to any lawful agreement otherwise permitted. The tribunal may allocate arbitration costs and legal expenses in accordance with applicable law and the circumstances of the case. The award shall be binding and enforceable subject to the applicable law.

10. Survival and continued performance. This clause shall survive the expiry or termination of this Agreement to the extent necessary to resolve disputes arising from it. During a Dispute, the Parties shall continue undisputed contractual obligations where reasonably practicable and lawful, without prejudice to their rights and remedies.

Drafting note: The proposed periods, single-arbitrator arrangement, and institutional mediation approach are illustrative. The final clause should identify an appropriate seat and institution where relevant, address cross-border enforcement, and account for the applicable rules on limitation, stamping, arbitrator eligibility, and interim relief.

8. Choosing the appropriate dispute resolution mechanism

Different biotech disputes benefit from different mechanisms.

Negotiation and mediation

Best for milestone renegotiation, delayed projects, research collaboration, and disputes where the parties want to preserve the business relationship.

Arbitration

Best for contested contractual liability, licence interpretation, unpaid royalties, damages, and complex commercial disputes requiring a binding decision.

Expert determination

Best for discrete technical questions, such as whether a product meets an agreed specification or a research milestone has been achieved.

Court or statutory proceedings

Necessary where the remedy sought falls within exclusive statutory jurisdiction, where a non-arbitrable dispute arises, or where court assistance is otherwise required.

9. Common drafting mistakes

Biotech companies should pay particular attention to the following risks.

1. Ambiguous arbitration language: Saying the parties “may agree to arbitrate later” may not establish a present, binding arbitration agreement.

2. No defined seat: The seat determines the juridical home of the arbitration and is important to supervisory jurisdiction.

3. Unilateral appointment of the sole arbitrator: This can undermine the validity of the appointment procedure under Indian law.

4. Unclear technical acceptance criteria: Without defined testing methods, sampling procedures, tolerances, and retesting rights, a scientific disagreement can become a prolonged legal dispute.

5. Unprotected confidential evidence: The clause should address disclosure restrictions, access to trade secrets, data protection, and secure handling of biological samples.

6. Inadequate treatment of urgent relief: Delays can result in destruction of evidence, loss of confidential information, or irreversible harm to a commercial relationship.

7. Failure to address statutory limits: Private dispute-resolution language cannot eliminate mandatory regulatory duties or guarantee that every intellectual property issue is arbitrable.

8. Unclear time limits: Negotiation and mediation procedures should not unintentionally create disputes over limitation periods or allow a party to delay arbitration indefinitely.

9. Ignoring non-signatories: A contract may involve affiliates, research partners, subcontractors, or investors who have not signed the arbitration agreement. Their involvement does not automatically make them parties to the arbitration.

10. No cross-border enforcement plan: International licensing contracts should consider the governing law, arbitration seat, enforceability of the award, and the legal status of the parties and assets in relevant jurisdictions.

10. Legal remedies and enforcement

Depending on the contract and applicable law, remedies may include:

Damages for proven contractual loss.

Payment of outstanding royalties, milestones, or invoices.

Contractual indemnification.

Declarations concerning contractual rights and obligations.

Specific performance where legally available.

Interim injunctions or other protective measures.

Preservation or return of confidential information and materials.

Costs and interest where legally permissible.

Under Sections 34 and 36 of the Arbitration and Conciliation Act, 1996, an award may be challenged on specified statutory grounds and, subject to the Act, enforced as a court decree. Section 34 does not provide a general appeal on the merits simply because a party disagrees with the tribunal's findings.

Indian Kanoon+1

The appropriate remedy will depend on the nature of the claim. An award directing payment of contractual royalties is different from an order purporting to revoke a regulatory approval or determine the rights of persons who were not parties to the proceedings.

11. Conclusion

Biotech contract dispute resolution clauses should integrate commercial certainty, scientific expertise, confidentiality, procedural fairness, and compliance with mandatory law.

The principal lessons from the cases are:

Vidya Drolia supports arbitration where a valid agreement covers an arbitrable dispute, while preserving statutory exceptions.

Perkins Eastman emphasizes impartiality in arbitrator appointment.

Indus Biotech illustrates the relationship between arbitration and statutory insolvency proceedings.

Trimex International demonstrates the potential enforceability of arbitration agreements formed through commercial communications.

Alchemist Hospitals illustrates the need for precise and coherent dispute-resolution wording.

Amgen v. Apotex demonstrates that private agreements cannot displace mandatory regulatory requirements.

The most effective clause is not necessarily the longest one. It is the one that identifies the disputes it covers, provides a clear procedure, protects scientific and confidential evidence, preserves urgent remedies, and respects the limits of the applicable law.

This is a general legal explanation for academic and contract-drafting purposes, not an opinion on a particular contract. The cited decisions should be checked against their full judgments and subsequent legal developments before being relied upon in litigation or formal legal advice.